Incruse Ellipta

How Hard Is It to Find Incruse Ellipta in Stock?

As of early 2026, Incruse Ellipta is not on the FDA's official drug shortage list and GlaxoSmithKline has not declared a manufacturing shortage. However, patients frequently experience localized difficulty finding it at their pharmacy. Incruse Ellipta is a brand-name-only LAMA inhaler with no generic, which means pharmacies stock it based solely on local patient demand. Many pharmacies prioritize higher-volume combination inhalers (Anoro Ellipta, Trelegy Ellipta) and may not regularly carry Incruse Ellipta monotherapy.

Patients in suburban, rural, or lower-density areas may be more likely to encounter stockouts at their usual pharmacy. Urban pharmacies with higher COPD patient volumes tend to stock it more consistently. Insurance-related issues — including prior authorization requirements and formulary tier restrictions — can also make it appear unavailable when the issue is actually a coverage denial.

If you're having trouble finding Incruse Ellipta at your pharmacy, medfinder can help. medfinder contacts pharmacies near your zip code to check which ones can fill your prescription and texts you the results — saving you hours of phone calls.

Who Can Prescribe Incruse Ellipta?

Incruse Ellipta (umeclidinium) is not a controlled substance and has no DEA scheduling. This means any licensed healthcare provider with standard prescribing authority can prescribe it — no special DEA certification or REMS program is required. The medication is appropriate for adults with confirmed COPD diagnosis.

Types of providers who commonly prescribe Incruse Ellipta include:

• Pulmonologists — lung specialists managing moderate to severe COPD
• Primary care physicians — family medicine and internal medicine doctors managing mild to moderate COPD in primary care
• Geriatricians — specialists in elderly care who frequently manage COPD in older adults
• Nurse practitioners (NPs) and physician assistants (PAs) — advanced practice providers with full or collaborative prescribing authority in most U.S. states

Telehealth is a viable option for Incruse Ellipta prescriptions. Since umeclidinium is not a controlled substance, it can be prescribed through virtual visits in most states. Telehealth providers can evaluate COPD symptoms, review existing pulmonary function test results, and renew or initiate maintenance inhaler prescriptions via video consultation — making access easier for patients in rural areas or those with mobility limitations.

Is Incruse Ellipta a Controlled Substance?

No. Incruse Ellipta (umeclidinium) is not a controlled substance and has no DEA schedule. There are no federal prescribing restrictions beyond standard medical licensure for this medication. Any licensed healthcare provider with prescribing authority — including primary care physicians, nurse practitioners, and physician assistants — can write a prescription for Incruse Ellipta without special DEA registration or certification.

Because it is not a controlled substance, Incruse Ellipta can also be prescribed via telehealth in most U.S. states, making it accessible through virtual pulmonology and primary care visits. There are no restrictions on refills beyond standard insurance plan rules (such as quantity limits or prior authorization requirements). Prescriptions can typically be refilled for up to one year from the date of the original prescription, depending on your state.

Common Side Effects of Incruse Ellipta

In clinical trials, the most common adverse reactions with Incruse Ellipta 62.5 mcg (occurring in ≥2% of patients and more frequently than placebo) were:

• Nasopharyngitis (common cold symptoms) — 8%
• Upper respiratory tract infection — 5%
• Cough — 3%
• Arthralgia (joint pain) — 2%
• Pharyngitis, tachycardia, upper abdominal pain, toothache — 1% each
• Dry mouth, headache, dizziness (anticholinergic class effects)

Serious Side Effects

Contact your doctor or seek emergency care immediately for:

• Paradoxical bronchospasm — sudden worsening of breathing immediately after inhaling; discontinue use immediately
• Urinary retention — difficulty urinating, weak urine stream; risk increased in patients with prostate enlargement
• Worsening narrow-angle glaucoma — eye pain, blurred vision, visual halos, red eyes
• Anaphylaxis — severe allergic reaction; risk higher in patients with severe milk protein allergy (lactose contains milk proteins)
• Atrial fibrillation — irregular heartbeat (rare, <1% in efficacy trials)

Final Thoughts on Incruse Ellipta

Incruse Ellipta (umeclidinium) is a well-tolerated, once-daily LAMA inhaler that plays an important role in the maintenance management of COPD. Its once-daily dosing, clinically proven bronchodilation, and the convenience of the pre-loaded Ellipta device make it a practical option for patients with moderate to severe COPD who need long-term airway management.

The primary challenges patients face with Incruse Ellipta in 2026 are cost and pharmacy availability. As a brand-name-only product with no generic available until at least December 2027, it retails at $350–$415 per 30-day inhaler. The GSK 'Pay No More Than $35' savings coupon provides significant relief for commercially insured patients, and the GSK For You Patient Assistance Program supports uninsured and underinsured individuals who qualify. GoodRx coupons offer an accessible middle-ground for those who don't qualify for manufacturer programs.

If you're struggling to find Incruse Ellipta at your local pharmacy, start your search early — before you run out of doses. Use medfinder to identify which pharmacies near you currently have it in stock without making call after call. Your COPD treatment depends on consistent daily use — don't let a stocking issue interrupt your therapy.